News | December 15, 2025
Indoco receives EIR from the USFDA for its API manufacturing facility at Patalganga
Indoco received the Establishment Inspection Report from the USFDA for its API manufacturing facility
Indoco received the Establishment Inspection Report from the USFDA for its API manufacturing facility
The inspection concluded with one minor observation in Form 483
This approval confirms the facility's compliance with FDA quality standards and regulatory requirements
The new site will produce next-generation synthetic medicine active pharmaceutical ingredients
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
Captured microbes are then neutralized on engineered microbicidal surfaces
VitiPure serves as essential solubilizers, emulsifiers, and bioavailability enhancers in drug formulations
Ipca Laboratories receives three observations from USFDA for API facility at Tarapur
The center will offer training to super-specialist doctors and healthcare professionals in various fields
Senores Pharmaceuticals is poised to accelerate its presence in the Asia-Pacific region
Subscribe To Our Newsletter & Stay Updated
